FindTrial
Sign In

LEVETERACETAM VS SODIUM VALPROATE

Open labeled randomized controlled trial comparing efficacy of oral levetiracetam v/s sodium valproate as first Line monotherapy in newly diagnosed generalized Epilepsy in children. - LEV VAL2019

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027792
Enrollment
100
Registered
2020-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Intervention1: Tablet or Syrup levetirecetam: levetirecetam given at 20 to 70 m/k/d to epileptic children for 1 year Control Intervention1: Tablet or syrup sodium valproate: sodium valproate given 15

Sponsors

government medical college and hospital aurangabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children with age two years and above diagnosed with generalized epilepsy attending Pediatric OPD and IPD at tertiary care hospital

Exclusion criteria

Exclusion criteria: 1 children with age less than 2 yearâ??s. 2 children with already on anti-epileptic drug 3 children with epilepsy syndrome 4 children with genetic disorder 5 children with chronic liver disease Or chronic kidney disease

Design outcomes

Primary

MeasureTime frame
To compare effect of oral levetiracetram v/s soduim valproate as first line monotherapy in newly diagnosed generalised epilepsy in children Timepoint: 18 months—

Secondary

MeasureTime frame
1. To study the side effect of levetiracetam and sodium valproateTimepoint: 18 months—

Countries

India

Contacts

Public ContactPRITAMKUMAR BHAGWAN CHIMANE

GOVERNMENT MEDICAL COLLEGE AURANGABAD

amol5054@gmail.com9404646465

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026